sIBM remains a challenging muscle disease in which inflammatory features coexist with degeneration. Although evidence indicates that there is interplay between the inflammatory mediators ...

The distinction between sIBM and the other, mostly hereditary vacuolar myopathies, such as myofibrillar myopathies or hereditary inclusion body myopathy with mutations in the glucosamine (UDP-N ...

Introduction: We aimed to identify B-cell-mediated immunomechanisms in inclusion body myositis (IBM) and polymyositis (PM) as part of the complex pathophysiology. Materials and methods: Human primary ...

Ulviprubart is under clinical development by Abcuro and currently in Phase III for Inclusion Body Myositis (IBM). According to GlobalData, Phase III drugs for Inclusion Body Myositis (IBM) does not ...

He revealed in 2019 that he had a degenerative muscle disease called inclusion body myositis, but plans a tour leading up to his induction — The Positively Thankful Tour, which hits South ...

This can help us make a better choice from among the various ways we currently measure the severity of a muscle disease such as inclusion body myositis (IBM). However, we cannot assume that QoL in IBM ...